Medacta's Five-Year Low Meets Its Best Half: The ASC Leak Nobody Prices

Double-digit growth and a 28% constant-currency margin — undercut by a U.S. base quietly walking out the hospital door.

MOVE.SW · Earnings Call · 2026-09-09

A Five-Year Low, Against the Best Half in History

Medacta's H1 2026 lands in an awkward spot. The Swiss orthopedics maker still outgrew its end market — revenue of EUR 368 million, up almost 10% in constant currency — still printed a ~27.8% constant-currency adjusted EBITDA margin (EUR 97 million), and still confirmed both its 2026 and midterm guidance. Yet management openly called it the weakest half in years, because EMEA (+10%), APAC (+13.1%) and Latin America (+16.4%) all grew double digits while North America managed only about 7%. The U.S. market is the swing factor in the entire story.

But H1 was probably our worst semester in the last five years after COVID. And we were comparing it with the best semester of Medacta history, which was probably H1 2025.
Francesco Siccardi, CEO · 2026-09-09

No price-shape tape was served for the ticker here, so the read has to come straight from a transcript that is unusually candid about what actually broke.

The U.S. Isn't Cyclical — It's Structural

CEO Francesco Siccardi offers two explanations, and the second is the genuinely interesting one. First, the market itself is normalizing to a pre-COVID growth rate of roughly 2.5–3%, versus the abnormal 5–5.5% of the post-COVID recovery years — “a 3% U.S. market growth versus an expected 5%, 5.5%” — Francesco Siccardi, CEO · 2026-09-09. That part is macro, and every orthopedics name is living it. Second — and this is company-unique — a hospital volume migration is quietly bleeding the base. Medacta serves surgeons inside ambulatory surgery centers, where procedures are more profitable for the surgeon. When those same surgeons abandon their hospital lists, the hospital volume does not follow Medacta: “The surgeons picking up those hospital volumes were not Medacta customers, so we have seen some attrition.” — Francesco Siccardi, CEO · 2026-09-09

They can drop their hospital volume because they make significantly more money in an ASC setting. Even by doing 80% of the volume they were doing before, they probably make more than what they were doing before in working in a hospital, significantly more.
Francesco Siccardi, CEO · 2026-09-09

That mechanism is exactly the kind of thing a generic "macro softness" sentence would bury. So base attrition is the keyword to watch — new to the company's lexicon, and grounded in a cause rather than a mood. Management says it has studied the pattern customer-by-customer and expects it to "significantly reduce" in H2, helped by a re-accelerating hip franchise (the triple-tapered Infinity stem, now in full U.S. and Japan release) and a new shoulder offering aimed at Stryker's turf.

India, and an In-House Religion

The offset story is more constructive. Medacta just cleared regulatory approval for its knees in India — its most strategic line — with shipping to begin in September. Siccardi frames a market of roughly 100 million procedures growing 15%+, at what amounts to European pricing. That is a genuine new-market vector, not a line extension. And against a backdrop where peers are paying up for M&A — he cites an Essential Spine deal at "EUR 150+ million" — Siccardi doubles down on internal R&D: “every time I look at price points paid for M&A, for technology, for products, the return on invested capital when we do it internally is incredibly better.” — Francesco Siccardi, CEO · 2026-09-09 The company is building its own robotics platform "pretty soon," and leans on enabling technology and a Kinematic Alignment knee implant to keep its growth multiple above the market.

The Margin Math, and a Global Fuel Tax

Gross margin fell to 65.2% from 68.3%. CFO Corrado Farsetta splits the roughly 3-point reduction into a 1.3pp FX hit, 0.5pp of price erosion, and 1.3pp of adverse geo mix and product mix — less U.S., more sports medicine, and a heavier instrument depreciation load. Working capital swelled to fund new customers and the India entry, dragging operating cash flow to EUR 56 million from EUR 73 million and putting free cash flow at negative EUR 18.6 million; leverage ticked to 1.2x net debt/adjusted EBITDA from 0.9x. Not alarming, but a visible wobble. One cross-current worth flagging: rising fuel costs are bleeding into variable transportation expense, the same high fuel costs theme that surfaced across the broader market this year and echoed by other reporters citing freight surcharges. Medacta, notably, says it is "not impacted by the U.S. tariffs" — a sharp contrast to consumer names like AEO, ASO and SIG, which spent their quarters parsing tariff refunds. Not every multinational is hostage to the same trade noise.

What Matters

Guidance of 10–14% revenue growth and ~50 basis points of constant-currency EBITDA expansion hinges entirely on an H2 U.S. re-acceleration that management openly calls "not easy." The bull case is that ASC attrition is temporary and India plus in-house innovation carry the midterm 12–15% CAGR. The bear case is that a structurally slower U.S. joint market has simply caught up with a serial share-gainer. This is a company-specific leak, not sector boilerplate — which is precisely why it's worth watching.